CN101491595A - Medicine of effective fractions of compounded prescription of Huomai Tiaozhi capsule and preparation technology thereof - Google Patents
Medicine of effective fractions of compounded prescription of Huomai Tiaozhi capsule and preparation technology thereof Download PDFInfo
- Publication number
- CN101491595A CN101491595A CNA200910004783XA CN200910004783A CN101491595A CN 101491595 A CN101491595 A CN 101491595A CN A200910004783X A CNA200910004783X A CN A200910004783XA CN 200910004783 A CN200910004783 A CN 200910004783A CN 101491595 A CN101491595 A CN 101491595A
- Authority
- CN
- China
- Prior art keywords
- ethanol
- total organic
- organic acids
- filtrate
- total
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a drug for an effective fraction group of a pulse-activating and fat-regulating capsule compound and a process for preparing the same. The effective fraction group comprises total saponin and total organic acid; drugs for preparing the total saponin comprise astragalus root, radix codonopsis pilosulae or Wu Chia Pee, radix salivae miltiorrhizae, turmeric or hawkthorn and caltrop or radices puerarire; drugs for preparing the total organic acid comprise privet and rhubarb or semen cassiae torae; the drugs for preparing the total saponin are mixed, extracted with water, filtered and subjected to ethanol precipitation; a water bath concentrated solution of an ethanol precipitation filtrate is subjected to macroporous resin column and elution by distilled water and ethanol sequentially; an eluant is evaporated to prepare the total saponin; the drugs for preparing the total organic acid are mixed, extracted by ethanol and filtered; a filtrate is condensed in a water bath, is subjected to macroporous resin column and gradient elution by distilled water and ethanol sequentially; an eluant is evaporated to prepare the total organic acid; and the total saponin and the total organic acid are mixed to prepare the effective fraction group. A drug formula totally adopts pure natural Chinese medicine materials, reduces fat, protects liver and has no toxicity and no side effect on human body, simple preparation process, easy operation and high extraction efficiency.
Description
The applying date of original application: on January 12nd, 2007
Application number: 200710008433.1
Invention and created name: the pharmaceutical formulation and the preparation technology of the arteries and veins blood fat regulating capsule compound effective site group of living
Technical field
The present invention relates to the prescription and the preparation technology of medicine, relate to a kind of medicine and preparation technology of the arteries and veins blood fat regulating capsule compound effective site group of living more specifically.
Background technology
At present, along with the raising of people's living standard, intake higher fatty acid, high heat food also increases day by day.The sickness rate of diseases such as fatty liver, hyperlipidemia, obesity, arteriosclerosis, cerebral thrombosis, coronary heart disease increases year by year, and is rejuvenation trend.Generally adopt Western medicine to carry out blood fat reducing treatment clinically,, take for a long time and can produce a lot of toxic and side effects, as liver, kidney being caused damage etc. human body based on cholesterol reducing or triglyceride.
Summary of the invention
Goal of the invention of the present invention is at the problems referred to above, and a kind of medicine and preparation technology of the arteries and veins blood fat regulating capsule compound effective site group of living is provided, and is intended to reach the purpose that blood fat reducing protects the liver again.
The present invention prepares the pharmaceutical formulation of arteries and veins blood fat regulating capsule compound effective site group alive, and wherein effective part group is total saponins and total organic acids; The percentage by weight of the pharmaceutical formulation component of preparation total saponins is: the Radix Astragali or Radix Codonopsis or Cortex Acanthopancis 30～45%, Radix Salviae Miltiorrhizae or Rhizoma Curcumae Longae or Fructus Crataegi 30～45%, Fructus Tribuli or Radix Puerariae 10～25%; The percentage by weight of the pharmaceutical formulation component of preparation total organic acids is: Fructus Ligustri Lucidi 80～90%, Radix Et Rhizoma Rhei or Semen Cassiae 10～20%.
Step of preparation process of the present invention is:
1) processing step of preparation total saponins is: with the Radix Astragali or Radix Codonopsis or Cortex Acanthopancis, Radix Salviae Miltiorrhizae or Rhizoma Curcumae Longae or Fructus Crataegi, Fructus Tribuli or Radix Puerariae mix by above-mentioned prescription, with with raw material weight than the water extraction 1～3 time that is 8～12 times of amounts, each 0.5～1.5 hour, merge extractive liquid,, filter, filtrate is 50～90% ethanol precipitate with ethanol with concentration, standing over night, filter, reclaim precipitate with ethanol filtrate, precipitate with ethanol filtrate concentrated and be settled to 100 ℃ of boiling water-baths contain the concentrated solution that total saponins concentration is 0.5～2g/ml, with AB-S type macroporous adsorptive resins on the concentrated solution, be the distilled water of 6～10 times of resin volumes and 30～70% ethanol elution with volume successively, elution flow rate 1～3ml/min, collect 30～70% ethanol elution, eluent is made total saponins at 100 ℃ of boiling water bath methods;
2) processing step of preparation total organic acids is: Fructus Ligustri Lucidi, Radix Et Rhizoma Rhei or Semen Cassiae are mixed by above-mentioned prescription, with with raw material weight than 50～95% alcohol reflux 1～3 time that are 6～10 times of amounts, each 1～2h, merge extractive liquid,, filter, reclaim filtrate, filtrate is concentrated and is settled to 100 ℃ of boiling water-bath contain the concentrated solution that total organic acids concentration is 0.5～2g/ml; With AB-S type macroporous adsorptive resins on the concentrated solution, be distilled water, 10～30% ethanol and 70～95% ethanol gradient elutions of 6～10 times of resin volumes successively with volume, elution flow rate is 1～3ml/min, collect 70～95% ethanol elution, eluent is made total organic acids at 100 ℃ of boiling water bath methods;
3) be that 1: 1～10: 1 total saponins and total organic acids is mixed and made into effective part group with weight ratio.
Remarkable advantage of the present invention is: this pharmaceutical formulation all is the natural Chinese medicines material, and not only blood fat reducing but also protect the liver has no side effect to human body, and preparation technology is simple, operation, extraction efficiency height easily.
The specific embodiment
With the Radix Astragali or Radix Codonopsis or Cortex Acanthopancis, Radix Salviae Miltiorrhizae or Rhizoma Curcumae Longae or Fructus Crataegi, Fructus Tribuli or Radix Puerariae mix by above-mentioned prescription, with with raw material weight than the water extraction 1～3 time that is 8～12 times of amounts, each 0.5～1.5 hour, merge extractive liquid,, filter, filtrate is 50～90% ethanol precipitate with ethanol with concentration, standing over night, filter, reclaim precipitate with ethanol filtrate, precipitate with ethanol filtrate concentrated and be settled to 100 ℃ of boiling water-baths contain the concentrated solution that total saponins concentration is 0.5～2g/ml, with AB-S type macroporous adsorptive resins on the concentrated solution, be the distilled water of 6～10 times of resin volumes and 30～70% ethanol elution with volume successively, elution flow rate 1～3ml/min, collect 30～70% ethanol elution, eluent is made total saponins at 100 ℃ of boiling water bath methods.
Fructus Ligustri Lucidi, Radix Et Rhizoma Rhei or Semen Cassiae are mixed by above-mentioned prescription, with with raw material weight than 50～95% alcohol reflux 1～3 time that are 6～10 times of amounts, each 1～2h, merge extractive liquid,, filter, reclaim filtrate, filtrate is concentrated and is settled to 100 ℃ of boiling water-bath contain the concentrated solution that total organic acids concentration is 0.5～2g/ml; With AB-S type macroporous adsorptive resins on the concentrated solution, be distilled water, 10～30% ethanol and 70～95% ethanol gradient elutions of 6～10 times of resin volumes successively with volume, elution flow rate is 1～3ml/min, collect 70～95% ethanol elution, eluent is made total organic acids at 100 ℃ of boiling water bath methods.
With weight ratio is that 1: 1～10: 1 total saponins and total organic acids is mixed and made into effective part group.
Wherein, used medical material Fructus Ligustri Lucidi is mature fruit or the dry blade of Fructus Ligustri Lucidi Ligustrum lucidum.Ait.; The Radix Astragali be adopt leguminous plant Radix Astagali Astragalus membranaceus (Fisch.) Bge, Var mongholicus (Bge) Hsio or Radix Astragali Astragalus membranaceus (Fisch) Bge, dry root; Radix Codonopsis is the root that adopts campanulaceae plant Radix Codonopsis Codonopsis pilosula (Franch.) Nannf., plain flower Radix Codonopsis C.Pilosula Nannf.Var.modesta (Nannf.) L.T.Shen or radix codonpsis tangshen C.tangshen Oliv.; Cortex Acanthopancis is the dry root bark that adopts Araliaceae acanthopanax gracilistylus Acanthopanax gracilistylusW.W.Smith; Radix Salviae Miltiorrhizae is exsiccant and the rhizome that adopts labiate Radix Salviae Miltiorrhizae Salvia miltiorrhiza Bge.; Rhizoma Curcumae Longae is to adopt zingiberaceous plant Rhizoma Curcumae Longae Curcuma longa.L. rhizome; Fructus Crataegi is the mature fruit that adopts rosaceous plant Fructus Pyri Pashiae Crataegus pinnatifida Bge.var.major N.E.Br. or Fructus Crataegi C.pinnatifida Bge.; Fructus Tribuli is the fruit that adopts zygophyllaceae plant Fructus Tribuli Tribulus terrestris L.; Radix Puerariae is the dry root that adopts legume pueraria lobata Pueraria lobata (Willd.) Ohwi or Radix Puerariae rattan Puerariathomsonii Benth.; Radix Et Rhizoma Rhei is the dry root and rhizome that adopts polygonum rheum palmatum Rheum palmatum L., Rheum tanguticum R.tanguticum Maxim.ex Balf. or Rheum officinale R.officinale Baill.; Semen Cassiae is the dry mature seed that adopts leguminous plant Semen Cassiae Cassia obtusifolia L. or little Semen Cassiae C.tora L..
The consumption of resin is 3: 10 with the weight ratio of preparation total saponins raw material consumption in the processing step of preparation total saponins, and the consumption of resin is 3: 5 with the weight ratio of preparation total organic acids raw material consumption in the processing step of preparation total organic acids.
Embodiment 1
With the Radix Astragali, Radix Salviae Miltiorrhizae, Fructus Tribuli mixes by above-mentioned prescription, with with raw material weight than the water extraction 2 times that is 8 times of amounts, each 1 hour, merge extractive liquid,, filter, filtrate is 70% ethanol precipitate with ethanol with concentration, standing over night is filtered, and reclaims precipitate with ethanol filtrate, precipitate with ethanol filtrate concentrated and be settled to 100 ℃ of boiling water-baths contain the concentrated solution that total saponins concentration is 1g/ml, with AB-S type macroporous adsorptive resins on the concentrated solution, be the distilled water of 8 times of resin volumes and 60% ethanol elution with volume successively, elution flow rate 1.5ml/min, collect 60% ethanol elution, eluent is made total saponins at 100 ℃ of boiling water bath methods.
Fructus Ligustri Lucidi, Radix Et Rhizoma Rhei are mixed by above-mentioned prescription, use with raw material weight than 80% alcohol reflux 2 times that is 8 times of amounts, 1h at every turn, merge extractive liquid,, filtrate is reclaimed in filtration, filtrate is concentrated and is settled to 100 ℃ of boiling water-bath contain the concentrated solution that total organic acids concentration is 1g/ml; With AB-S type macroporous adsorptive resins on the concentrated solution, be distilled water, 10% ethanol and 70% ethanol gradient elution of 10 times of resin volumes successively with volume, elution flow rate is 1.5ml/min, collects 70% ethanol elution, and eluent makes total organic acids at 100 ℃ of boiling water bath methods.
With weight ratio is that 1: 1 total saponins and total organic acids is mixed and made into effective part group.
Embodiment 2
With Radix Codonopsis, Radix Salviae Miltiorrhizae, Fructus Tribuli mixes by above-mentioned prescription, with with raw material weight than the water extraction 2 times that is 10 times of amounts, each 1 hour, merge extractive liquid,, filter, filtrate is 80% ethanol precipitate with ethanol with concentration, standing over night is filtered, and reclaims precipitate with ethanol filtrate, precipitate with ethanol filtrate concentrated and be settled to 100 ℃ of boiling water-baths contain the concentrated solution that total saponins concentration is 1g/ml, with AB-S type macroporous adsorptive resins on the concentrated solution, be the distilled water of 8 times of resin volumes and 60% ethanol elution with volume successively, elution flow rate 1.5ml/min, collect 60% ethanol elution, eluent is made total saponins at 100 ℃ of boiling water bath methods.
Fructus Ligustri Lucidi, Radix Et Rhizoma Rhei are mixed by above-mentioned prescription, use with raw material weight than 80% alcohol reflux 2 times that is 8 times of amounts, 1h at every turn, merge extractive liquid,, filtrate is reclaimed in filtration, filtrate is concentrated and is settled to 100 ℃ of boiling water-bath contain the concentrated solution that total organic acids concentration is 1g/ml; With AB-S type macroporous adsorptive resins on the concentrated solution, be distilled water, 10% ethanol and 70% ethanol gradient elution of 10 times of resin volumes successively with volume, elution flow rate is 1.5ml/min, collects 70% ethanol elution, and eluent is made total organic acids at 100 ℃ of boiling water bath methods.
With weight ratio is that 1: 1 total saponins and total organic acids is mixed and made into effective part group.
Embodiment 3
With the Radix Astragali, Fructus Crataegi, Fructus Tribuli mixes by above-mentioned prescription, with with raw material weight than the water extraction 3 times that is 8 times of amounts, each 1 hour, merge extractive liquid,, filter, filtrate is 75% ethanol precipitate with ethanol with concentration, standing over night is filtered, and reclaims precipitate with ethanol filtrate, precipitate with ethanol filtrate concentrated and be settled to 100 ℃ of boiling water-baths contain the concentrated solution that total saponins concentration is 1g/ml, with AB-S type macroporous adsorptive resins on the concentrated solution, be the distilled water of 8 times of resin volumes and 60% ethanol elution with volume successively, elution flow rate 1.5ml/min, collect 60% ethanol elution, eluent is made total saponins at 100 ℃ of boiling water bath methods.
Fructus Ligustri Lucidi, Radix Et Rhizoma Rhei are mixed by above-mentioned prescription, use with raw material weight than 80% alcohol reflux 2 times that is 8 times of amounts, 1h at every turn, merge extractive liquid,, filtrate is reclaimed in filtration, filtrate is concentrated and is settled to 100 ℃ of boiling water-bath contain the concentrated solution that total organic acids concentration is 1g/ml; With AB-S type macroporous adsorptive resins on the concentrated solution, be distilled water, 10% ethanol and 70% ethanol gradient elution of 10 times of resin volumes successively with volume, elution flow rate is 1.5ml/min, collects 70% ethanol elution, and eluent is made total organic acids at 100 ℃ of boiling water bath methods.
With weight ratio is that 1: 1 total saponins and total organic acids is mixed and made into effective part group.
The pharmacological research test of effective part group
(1) effective part group is to the influence of rat fat
The rat adaptability fed for 1 week, was divided into normal blank group and modeling group at random.Normal rats is irritated the stomach normal saline; Modeling group rat is adopted and irritates the modeling of stomach lipomul method, and lipomul is formed: 10g cholesterol, 20g Adeps Sus domestica, 2g sodium cholate, 1g methylthiouracil, 20ml tween 80,20ml propylene glycol add water and be mixed into 100ml in right amount.Feed after 7 days, eye socket is got blood, surveys serum TC, TG.
According to the body weight of modeling group rat and TC, TG level, be divided into 6 groups at random.Blank group, model group, fluvastatin group (3.6mgkg
-1), former side organizes (1400mgkg
-1), effective part group high dose group (375mgkg
-1), dosage group (188mgkg in the effective part group
-1), effective part group low dose group (62.5mgkg
-1), 10 every group.
Rat is given different sample medicinal liquids by different groups, twice of normal control group every filling stomach distilled water every day (1ml/100g); Model group every filling stomach lipomul every day and distilled water are respectively once; Administration group every filling stomach lipomul every day and different pharmaceutical are respectively once.Feed continuously and administration 30d.And claim its body weight respectively at 0d, 7d, 14d, 21d, 28d.Fasting 12 hours (can't help water) after the last administration, the back broken end of weighing is got blood, and separation of serum is measured the every index of blood fat respectively.T-CHOL (TC) is measured with direct method with direct method mensuration, low-density lipoprotein cholesterol (LDL-C) with oxidation enzymatic assays, HDL-C (HDL-C) with oxidation enzymatic assays, triglyceride (TG), the results are shown in Table 1.
The effect of table 1 effective part group treatment experimental rat hyperlipemia
Annotate: the t check, each administration group and model group be △ P＜0.05 relatively, △ △ P＜0.01; With former side's group comparison ▲ P＜0.05; Compare with the blank group
*P＜0.05,
*P＜0.01.
Table 1 result shows: model group Serum TC, LDL content are apparently higher than blank group (P＜0.01).Each dosage group of effective part group and fluvastatin group can make Serum TC, TG, LDL-C content obviously reduce (P＜0.05～0.01), high dose group Serum TC, LDL content relatively have significant difference (P＜0.05) with model group, action intensity and fluvastatin are suitable, and organize more also there was no significant difference (P＞0.05) with former side.The prompting extract part is the active site of full presciption medicine effect effect, imitates no significant difference with full presciption medicine.
(2) effective part group is to the influence of rat acute hepatic injury:
Get 30 rat male and female half and half, be divided into 3 groups at random, 10 every group.Blank group, model group are irritated stomach normal saline 10ml/kg/d, and stomach effective part group 375mg/kg/d irritates in effective site group.Each organizes continuous gastric infusion 7 days, and 1h is except that the blank group is irritated stomach Oleum Arachidis hypogaeae semen (5ml/kg) after the last time administration, and all the other each groups are all irritated stomach 25%CCl
4Peanut oil solution 5ml/kg, overnight fasting, broken end is got blood and is put to death animal behind the 16h, collects blood, and separation of serum is measured alanine aminotransferase (ALT), triglyceride (TG).The results are shown in Table 2.
Cut open the belly immediately after rat is put to death, take out liver and be dipped in 10% the neutral formalin solution, fix 3～4 days, the routine paraffin wax section, HE dyeing, the om observation hepatic tissue pathology changes.The hepar damnification grading is decided to be: hepatocyte edema quantity percentage ratio: 10～20%, 20～30%, 30～40% and 〉=50%; Hepatocyte diffusivity fat range degree: hepatocyte does not have the change of diffusivity fat, the interior rarely seen tiny fat of hepatocyte drips; Hepatocyte special mess degree of necrosis: hepatocyte does not have little focal necrosis; Accidental several necrocytosis kitchen ranges in the lobules of liver.The results are shown in Table 3.
Table 2 effective part group is to the influence of rat blood serum ALT, TG
Annotate: the t check, compare with the blank group
*P＜0.01; Compare △ P＜0.05, △ △ P＜0.01 with model group.
Table 2 result shows: model group rat blood serum ALT level significantly raises (P＜0.01) than the blank group, and CCl is described
4Cause acute liver damage modelling success.The rat blood serum ALT of effective site group level significantly reduces (P＜0.05) than model group, and the serum TG level obviously raises than model group, but not statistically significant (P＞0.05).
Table 3 effective part group is to the histological influence of experimental rat hepatic pathology
Histopathology result shows: (one) perusal: blank group finding liver is chocolate, its smooth surface, and matter is medium; The increase of model group liver is the dull gray redness, and very the person is grey yellowish red color, or sees the yellowish-brown fleck, and peplos is nervous, smooth, and matter is softer; Effective site group liver slightly increases, and the surface is chocolate or little Huang, or accidental yellowish-brown fleck, and peplos is nervous, and matter is soft slightly.(2) light microscopy checking: see liver rope queueing discipline under the blank group liver tissues of rats structure mirror, the hepatocyte form is normal, nucleus circle or oval, and placed in the middle, sinus hepaticus and portal area are no abnormal; The banded edema of the hepatocyte that visible level does not wait under the model arrangement of mirrors, cell rope arrangement disorder, and slight fat change of popularity and accidental little focal necrosis, most of banded edema expands for central authorities and to the portal area and prolongs; And effective site group hepatocyte edema quantity, fat change and little focal necrosis all obviously alleviate than model group, alleviate obviously with hepatocyte edema quantity especially, and most hepatocyte have confirmed that near the blank group effective part group is to CCL
4Cause hepatic injury and have protective effect.
Claims (4)
1. medicine of arteries and veins blood fat regulating capsule compound effective site group of living, it is characterized in that: described effective part group is total saponins and total organic acids; The percentage by weight of the pharmaceutical formulation component of described preparation total saponins is: Radix Codonopsis 30～45%, Radix Salviae Miltiorrhizae 30～45%, Fructus Tribuli 10～25%; The percentage by weight of the pharmaceutical formulation component of described preparation total organic acids is: Fructus Ligustri Lucidi 80～90%, Radix Et Rhizoma Rhei 10～20%.
2. the pharmaceutical formulation of arteries and veins blood fat regulating capsule compound effective site group alive according to claim 1 is characterized in that: described Fructus Ligustri Lucidi is mature fruit or the dry blade of Fructus Ligustri Lucidi.
3. preparation technology of arteries and veins blood fat regulating capsule compound effective site group that lives as claimed in claim 1 or 2, it is characterized in that: step of preparation process is:
1) processing step of preparation total saponins is: with Radix Codonopsis, Radix Salviae Miltiorrhizae, Fructus Tribuli mixes by above-mentioned prescription, with with raw material weight than the water extraction 1～3 time that is 8～12 times of amounts, each 0.5～1.5 hour, merge extractive liquid,, filter, filtrate is 50～90% ethanol precipitate with ethanol with concentration, standing over night, filter, reclaim precipitate with ethanol filtrate, precipitate with ethanol filtrate concentrated and be settled to 100 ℃ of boiling water-baths contain the concentrated solution that total saponins concentration is 0.5～2g/ml, with AB-S type macroporous adsorptive resins on the concentrated solution, be the distilled water of 6～10 times of resin volumes and 30～70% ethanol elution with volume successively, elution flow rate 1～3ml/min, collect 30～70% ethanol elution, eluent is made total saponins at 100 ℃ of boiling water bath methods;
2) processing step of preparation total organic acids is: Fructus Ligustri Lucidi, Radix Et Rhizoma Rhei are mixed by above-mentioned prescription, with with raw material weight than 50～95% alcohol reflux 1～3 time that are 6～10 times of amounts, each 1～2h, merge extractive liquid,, filter, reclaim filtrate, filtrate is concentrated and is settled to 100 ℃ of boiling water-bath contain the concentrated solution that total organic acids concentration is 0.5～2g/ml; With AB-S type macroporous adsorptive resins on the concentrated solution, be distilled water, 10～30% ethanol and 70～95% ethanol gradient elutions of 6～10 times of resin volumes successively with volume, elution flow rate is 1～3ml/min, collect 70～95% ethanol elution, eluent is made total organic acids at 100 ℃ of boiling water bath methods;
3) be that 1: 1～10: 1 total saponins and total organic acids is mixed and made into effective part group with weight ratio.
4. according to the preparation technology of the described arteries and veins blood fat regulating capsule compound effective site group alive of claim 3, it is characterized in that: the consumption of resin is 3: 10 with the weight ratio of preparation total saponins raw material consumption in the processing step of described preparation total saponins, and the consumption of resin is 3: 5 with the weight ratio of preparation total organic acids raw material consumption in the processing step of described preparation total organic acids.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910004783XA CN101491595B (en) | 2007-01-12 | 2007-01-12 | Medicine of effective fractions of compounded prescription of Huomai Tiaozhi capsule and preparation technology thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910004783XA CN101491595B (en) | 2007-01-12 | 2007-01-12 | Medicine of effective fractions of compounded prescription of Huomai Tiaozhi capsule and preparation technology thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200710008433A Division CN100998844B (en) | 2007-01-12 | 2007-01-12 | Medicinal formula of compound effective site group of huomai-tiaozhi capsule and its preparation technology |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101491595A true CN101491595A (en) | 2009-07-29 |
| CN101491595B CN101491595B (en) | 2011-11-30 |
Family
ID=40922495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910004783XA Expired - Fee Related CN101491595B (en) | 2007-01-12 | 2007-01-12 | Medicine of effective fractions of compounded prescription of Huomai Tiaozhi capsule and preparation technology thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101491595B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104288267A (en) * | 2013-07-16 | 2015-01-21 | 谷思瑞 | Traditional Chinese medicine tea having functions of lowering lipids and decreasing blood pressure |
| CN104474015A (en) * | 2014-12-21 | 2015-04-01 | 贵州苗侗百草医药发展有限公司 | Medicine for lowering blood pressure and blood fat and preparation method of medicine |
| CN104720050A (en) * | 2013-12-24 | 2015-06-24 | 曾正 | Traditional Chinese medicine vinegar agent for treating female kidney deficiency |
| CN104905372A (en) * | 2015-06-30 | 2015-09-16 | 青岛浩大海洋保健食品有限公司 | Abalone and sea cucumber compound wine with blood lipid regulation efficacy |
| CN105535866A (en) * | 2016-02-05 | 2016-05-04 | 陕西白鹿制药股份有限公司 | Medicine for treating hyperlipidemia and preparation method thereof |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102078562B (en) * | 2009-11-27 | 2011-12-21 | 许培斌 | Chinese medicinal oral liquid for treating children metabolic syndrome and preparation method thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1263502C (en) * | 2004-06-30 | 2006-07-12 | 曹琼 | Chinese traditional medicine for treating hypertension |
| CN1586580A (en) * | 2004-07-07 | 2005-03-02 | 香港养春堂中药有限公司 | Pill for fat reducing |
| CN1327882C (en) * | 2004-10-13 | 2007-07-25 | 于云龙 | Traditional Chinese medicinal formulation for treating cardiovascular and cerebrovascular disease |
-
2007
- 2007-01-12 CN CN200910004783XA patent/CN101491595B/en not_active Expired - Fee Related
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104288267A (en) * | 2013-07-16 | 2015-01-21 | 谷思瑞 | Traditional Chinese medicine tea having functions of lowering lipids and decreasing blood pressure |
| CN104720050A (en) * | 2013-12-24 | 2015-06-24 | 曾正 | Traditional Chinese medicine vinegar agent for treating female kidney deficiency |
| CN104474015A (en) * | 2014-12-21 | 2015-04-01 | 贵州苗侗百草医药发展有限公司 | Medicine for lowering blood pressure and blood fat and preparation method of medicine |
| CN104474015B (en) * | 2014-12-21 | 2018-08-24 | 贵州苗侗百草医药发展有限公司 | A kind of drug and preparation method thereof for blood fat-reducing blood pressure-decreasing |
| CN104905372A (en) * | 2015-06-30 | 2015-09-16 | 青岛浩大海洋保健食品有限公司 | Abalone and sea cucumber compound wine with blood lipid regulation efficacy |
| CN105535866A (en) * | 2016-02-05 | 2016-05-04 | 陕西白鹿制药股份有限公司 | Medicine for treating hyperlipidemia and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101491595B (en) | 2011-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102233119B (en) | Traditional Chinese medicine composition for treating fatty liver and preparation method thereof | |
| CN101837065B (en) | Medicine with anti-hepatitis, anti-tumour and organism immunity improving functions and preparation method thereof | |
| CN102631390B (en) | Preparation method of periploca forrestii schltr extract as well as product and application of periploca forrestii schltr extract | |
| CN101491595B (en) | Medicine of effective fractions of compounded prescription of Huomai Tiaozhi capsule and preparation technology thereof | |
| CN103933220B (en) | Medicine for treating climacteric syndrome | |
| CN103860699A (en) | Pharmaceutical composition for radically treating hypertension, hyperlipidemia and hyperglycemia | |
| CN100998844B (en) | Medicinal formula of compound effective site group of huomai-tiaozhi capsule and its preparation technology | |
| CN102488743A (en) | Chinese traditional medicine composition, preparation method thereof and Chinese traditional medicine preparation | |
| CN102247479B (en) | Antitumor strong medicine and preparation method thereof | |
| CN102362971B (en) | A kind of preparation method and preparation for the treatment of coronary heart disease Chinese medicine and effective chemical constituent thereof | |
| CN103933411A (en) | Traditional Chinese medicinal composition for treating fatty liver, and preparation method and use thereof | |
| CN1785249B (en) | Novel use of medicine composition containing red-rooted salvia | |
| CN100518809C (en) | Medicinal composition for curing diabetes and nephropathy and its preparing method | |
| CN100522230C (en) | Medicine for treating diabetes and hephrosis and its preparing method | |
| CN101342249B (en) | Chinese medicine formulations for treating hepatitis B and preparation method thereof | |
| CN109694393B (en) | A kind of extracting method and its application of stachyose | |
| CN101491608B (en) | Medicine of effective fractions of compounded prescription of Huomai Tiaozhi capsule and preparation technology thereof | |
| CN109224038A (en) | A kind of Chinese medicine composition of the evodia rutaecarpa containing guiding drug and its preparation method and application for treating obstruction of collaterals by blood stasis type liver fibrosis | |
| CN106309736B (en) | Anti-fatigue Chinese medicinal composition and its preparation method and application | |
| CN102008598A (en) | Blood fat-lowering and liver-protecting composite as well as preparation prepared thereby and preparation method of preparation | |
| CN103690768A (en) | Creeping liriope-figwort-milkvetch root soft capsules and preparation method thereof | |
| CN102641402A (en) | Preparation and quality control method of traditional Chinese medicine compound preparation for treating nephritis | |
| CN107744577B (en) | Traditional Chinese medicine composition for treating gastric mucosal injury | |
| CN101632829B (en) | Anti-hepatofibrosis traditional Chinese medicament composition, preparation method thereof and medicament preparation | |
| CN101234103B (en) | Total coumarin angelica dahurica composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20111130 Termination date: 20150112 |
|
| EXPY | Termination of patent right or utility model |